Cover Image
市場調查報告書

Hanmi Pharmaceuticals, Co. Ltd.的產品平台分析

Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251672
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
Hanmi Pharmaceuticals, Co. Ltd.的產品平台分析 Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2016
出版日期: 2016年05月31日 內容資訊: 英文 85 Pages
簡介

Hanmi Pharmaceuticals, Co. Ltd.是總公司在韓國製藥產品的製造企業。進行處方藥及OTC藥的製造,處方藥有抗菌劑、骨質疏鬆症、肝臟用營養補充品、制吐藥等。

本報告提供Hanmi Pharmaceuticals, Co. Ltd. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Hanmi Pharmaceuticals, Co. Ltd. 的基本資料

  • Hanmi Pharmaceuticals, Co. Ltd. 概要
  • 主要資訊
  • 企業資料

Hanmi Pharmaceuticals, Co. Ltd. :R&D概要

  • 主要的治療範圍

Hanmi Pharmaceuticals, Co. Ltd. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Hanmi Pharmaceuticals, Co. Ltd. :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Hanmi Pharmaceuticals, Co. Ltd. :藥物簡介

  • (montelukast sodium + levocetirizine dihydrochloride)
  • (paclitaxel + HM30181A)
  • HCP-1105
  • HCP-1302
  • HCP-1305
  • HCP-1306
  • HCP-1401
  • sildenafil citrate IMD
  • (aceclofenac + eperisone)
  • (Bacillus subtilis + mosapride + Streptococcus faecium)
  • HM-10460A
  • HM-10560A
  • HM-10660A
  • HM-11260C
  • poziotinib
  • KX-01
  • (ambroxol + levodropropizine)
  • (fluticasone propionate + salmeterol)
  • (irinotecan hydrochloride + HM30181A)
  • (metformin + rosuvastatin calcium)
  • epoetin alfa Long Acting
  • HCP-0904
  • HCP-1007
  • HCP-1303
  • HIP-0901
  • HM-12525A
  • HM-61713
  • HM-71224
  • insulin human Long Acting
  • (rosuvastatin calcium + fenofibric acid)
  • (tamsulosin + dutasteride)
  • exenatide + insulin human
  • HM-12160B
  • HM-12470
  • HM-47000
  • HM-95573
  • HM-12260B

Hanmi Pharmaceuticals, Co. Ltd. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Hanmi Pharmaceuticals, Co. Ltd. :最近的開發平台資訊

Hanmi Pharmaceuticals, Co. Ltd. :開發休止的計劃

Hanmi Pharmaceuticals, Co. Ltd. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08060CDB

Summary

Global Markets Direct's, 'Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2016', provides an overview of the Hanmi Pharmaceuticals, Co. Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Hanmi Pharmaceuticals, Co. Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Hanmi Pharmaceuticals, Co. Ltd.
  • The report provides overview of Hanmi Pharmaceuticals, Co. Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Hanmi Pharmaceuticals, Co. Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Hanmi Pharmaceuticals, Co. Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Hanmi Pharmaceuticals, Co. Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hanmi Pharmaceuticals, Co. Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hanmi Pharmaceuticals, Co. Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hanmi Pharmaceuticals, Co. Ltd. Snapshot
    • Hanmi Pharmaceuticals, Co. Ltd. Overview
    • Key Information
    • Key Facts
  • Hanmi Pharmaceuticals, Co. Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products Glance
    • Hanmi Pharmaceuticals, Co. Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Hanmi Pharmaceuticals, Co. Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Hanmi Pharmaceuticals, Co. Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Hanmi Pharmaceuticals, Co. Ltd. - Drug Profiles
    • HCP-1302
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (HM30181A + paclitaxel)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eflapegrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1105
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1303
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1305
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HGP-0816
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HGP-1207
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HIP-1402
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALG-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • efpegsomatropin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • olmutinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • poziotinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KX-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (HM30181A + irinotecan hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • amlodipine besylate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1405
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-12525A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-71224
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-95573
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BH-03004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics for Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 1 for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules 2 for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Acute Myeloid Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Fibrosis and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics to Target CTLA4 and TNF Alpha
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics to Target HER2 and CD3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics to Target HER2 and VEGFR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-12260B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target ROR Gamma
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Analysis
    • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Target
    • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Route of Administration
    • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Molecule Type
    • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action
  • Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates
  • Hanmi Pharmaceuticals, Co. Ltd. - Dormant Projects
  • Hanmi Pharmaceuticals, Co. Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hanmi Pharmaceuticals, Co. Ltd., Key Information
  • Hanmi Pharmaceuticals, Co. Ltd., Key Facts
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Indication, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Stage of Development, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Monotherapy Products in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Out-Licensed Products in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pre-Registration, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Phase III, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Phase II, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Phase I, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Preclinical, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Discovery, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Target, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Route of Administration, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Molecule Type, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Dormant Developmental Projects,2016
  • Hanmi Pharmaceuticals, Co. Ltd., Other Locations
  • Hanmi Pharmaceuticals, Co. Ltd., Subsidiaries

List of Figures

  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Top 10 Indication, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Stage of Development, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Monotherapy Products in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Out-Licensed Products in Pipeline, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Top 10 Target, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Route of Administration, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Molecule Type, 2016
  • Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top